Merit Medical Systems, Inc. (MMSI)
合理估值基本面
70
价格
$86.33
市值
$5.15B
第一部分 · 这家公司值多少
概览
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
BD's interventional and vascular access lines compete with Merit for the same hospital purchasing contracts on catheters, ports, drainage and biopsy products.
Boston Scientific sells competing peripheral intervention, embolization and endoscopy devices, the three areas where Merit generates most of its revenue.
Merit names Teleflex first among its rivals in both peripheral and cardiac intervention, where the two sell overlapping catheters, introducers and vascular access devices to the same interventional radiology and cardiology labs.
Cook Medical, privately held, is the one competitor Merit names in every product area — peripheral intervention, cardiac intervention, oncology and endoscopy — with a directly comparable catalogue of interventional catheters, guidewires and biopsy devices.
Medtronic competes with Merit in peripheral and cardiac intervention and, through its spine business, for the OEM and implant components Merit also supplies.
Terumo is named by Merit as a cardiac intervention competitor, selling rival radial access sheaths, guidewires and inflation devices to the same catheter labs, with particular strength in Japan and Europe.
资产负债表与流动性
营收
$1.58B
最近12个月（截至2026/6/30）
净利润
$146M
最近12个月（截至2026/6/30）
自由现金流
$216M
股东权益合计
$1.58B
负债合计
$1.10B
流动比率
4.20
利息覆盖率
6.34
债务/EBITDA
2.66
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$74.75
当前价格
$86.33
安全边际
-15.5%
公允价值区间
$48.58 - $100.91
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
35.49
ROE
8.1%
市净率（P/B）
3.07
P/FCF
25.34
毛利率
49.5%
ROIC
6.1%
盈利能力雷达图
价值创造（经济护城河）
ROIC
6.1%
WACC
7.3%
ROIC − WACC
-1.1 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（21）
- EPS shows upward trend
- EPS CAGR 7.91%
- Price CAGR 12.63%
- ROIC 6.1%
- Gross Margin 49.5%
- P/FCF 25.34
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 9.1%
- Revenue Growth 5Y 9.5%
- Analyst Consensus 82% Buy
- Earnings Surprise avg 11.9%
- Earnings Quality (OCF/NI) 1.95
- Share Dilution 1.7%
- Net Margin Trend 9.2% vs 8.3%
- Piotroski F-Score 7/9
未通过（5）
- P/B Ratio 3.07
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
不可用（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
财务状况强健
盈利质量
高质量：盈利有现金流支撑
股权稀释
股份数量稳定
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 58 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 46 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 64 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 52 |
| Mr. Neil W. Peterson | Senior Advisor | 59 |
| Mr. Jason Treft | Chief Information Officer | - |
| Ms. Sarah Comstock | Vice President of Global Communications | - |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | - |
| Mr. Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | - |
| Mr. Mark Butler | Executive Vice President of Merit Medical EMEA | - |
审计风险
2
董事会风险
2
薪酬风险
1
股东权利风险
4
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for MMSI, sourced from Markets Gazette.